Vargas Marcos Lahera, Cervantes Carlos Escobar, Hernando Carmen Alameda, Da Costa César Varela
Servicio de Endocrinología y Nutrición, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, España.
Endocrinol Nutr. 2009 Oct;56(8):412-7. doi: 10.1016/S1575-0922(09)72711-1.
High-dose cabergoline therapy has been related to cardiac valve regurgitation in patients with Parkinson's disease.
To perform a systematic analysis of reports on low-dose cabergoline treatment in hyperprolactinemia and its effect on the cardiac valves.
None of the seven reports analyzed, including 463 patients in total, found clinically significant valve regurgitation. Only one report found moderate tricuspid valve regurgitation, and other two reports found mild tricuspid valve regurgitation. An increase in the mitral tenting area was documented in only one of two reports. Valve thickening and calcifications were found in only one study.
Cabergoline seems to be safe at the doses employed in hyperprolactinemic patients. There is a higher prevalence of tricuspid regurgitation, detected by systematic echocardiography, but this abnormality is asymptomatic. Although prospective longitudinal studies are needed, vigilance of these patients is recommended, especially those treated with high-dose cabergoline.
高剂量卡麦角林疗法与帕金森病患者的心脏瓣膜反流有关。
对关于低剂量卡麦角林治疗高催乳素血症及其对心脏瓣膜影响的报告进行系统分析。
分析的7篇报告（共463例患者）均未发现具有临床意义的瓣膜反流。仅有1篇报告发现中度三尖瓣反流，另外2篇报告发现轻度三尖瓣反流。在2篇报告中仅有1篇记录到二尖瓣帐篷面积增加。仅在1项研究中发现瓣膜增厚和钙化。
在高催乳素血症患者所使用的剂量下，卡麦角林似乎是安全的。通过系统性超声心动图检测发现三尖瓣反流的患病率较高，但这种异常无症状。尽管需要进行前瞻性纵向研究，但建议对这些患者保持警惕，尤其是那些接受高剂量卡麦角林治疗的患者。
